NCT07352423

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN2230 in Healthy Adult Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Alexion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of single subcutaneous (SC) doses of ALXN2230 in healthy participants.

Detailed description

Part A of this study is expected to enroll approximately 40 participants (30 on ALXN2230 and 10 on placebo) across 5 cohorts and Part B is expected to enroll approximately 8 participants (6 on ALXN2230 and 2 on placebo) in 1 cohort.

Conditions

• Healthy Adult Participants

Interventions

Type	Name	Description
DRUG	ALXN2230	Participants will receive ALXN2230 via SC injection. Optional cohort will receive ALXN2230 via SC infusion.
DRUG	Placebo	Participants will receive placebo via SC injection. Optional cohort will receive placebo via SC infusion.

Timeline

• Start date: 2026-03-26
• Primary completion: 2026-12-23
• Completion: 2026-12-23
• First posted: 2026-01-20
• Last updated: 2026-04-09

Locations

1 site across 1 country: United Kingdom